The concept that cancer is a disease of genes, a dogma in molecular oncology, has now acquired an unprecedented clinical value and provides the rationale to set up a classification of tumours based on the presence of defined genetic lesions.
Thanks to these advances, the idea of giving a patient drugs tailored to the genetic makeup of the tumour is now becoming commonplace. The Conference will deal with tumour genotyping, identification of biomarkers for molecularly based patient stratification, investigation of the mechanisms of drug action and resistance.
The meeting will address the following issues, ‘from bench to bedside’, in three sessions:

(1) Cancer Genes: Drivers and Targets
(2) Personalised Cancer Medicine
(3) Tumour Heterogeneity and Resistance